Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Establishing the Epigenomic Landscape of Brain Metastases
EF 2020-21
Résumé
The spread of a cancer to a patient's brain, termed a brain metastasis, leads to significantly shorter patient survival. Although lung, breast, and melanoma tumours make up the majority of brain metastases, there is no reliable method to predict which specific patients who have these tumours will develop a spread to the brain. Modifications found in tumour DNA, specifically DNA methylation signatures, have been used to diagnose many brain tumour types and even to predict which meningiomas of the brain are likely to continue to grow and progress after surgery. Additionally, recent work has shown that these DNA methylation signatures can be identified in patient blood samples to avoid the need for invasive brain surgery to biopsy tumours. However, no studies have assessed whether DNA methylation signatures in cancer can predict whether patients will develop a brain metastasis later and are high risk. The inability to predict which patients will develop brain metastases limits our ability to best treat these patients to provide them with the best outcomes, since current practice is typically to treat brain metastases after they develop rather than to prevent them. Accordingly, this work aims to identify DNA methylation signatures in lung, breast, and melanoma cancers that are detectable in patient blood samples and that predict whether they will later metastasize to the brain in patients. By arming physicians with tools that provide this risk information for their patients after non-invasive blood sampling, the extent of treatment offered to patients can be matched to their level of risk and this may allow for strategies to prevent brain metastases in high risk patients. Overall, non-invasively determining a patient's risk for spread of their cancer to their brain allows for tailored treatment aiming to improve patient survival and quality of life.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
437169
Name
Zuccato Jeffrey A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Establishing the Epigenomic Landscape of Brain Metastases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Brain Metastasis; Cancer; Central Nervous System; Circulating Biomarkers; Molecular Epigenetics; Molecular Genetics; Outcome Prediction
Abstract
The spread of a cancer to a patient's brain, termed a brain metastasis, leads to significantly shorter patient survival. Although lung, breast, and melanoma tumours make up the majority of brain metastases, there is no reliable method to predict which specific patients who have these tumours will develop a spread to the brain. Modifications found in tumour DNA, specifically DNA methylation signatures, have been used to diagnose many brain tumour types and even to predict which meningiomas of the brain are likely to continue to grow and progress after surgery. Additionally, recent work has shown that these DNA methylation signatures can be identified in patient blood samples to avoid the need for invasive brain surgery to biopsy tumours. However, no studies have assessed whether DNA methylation signatures in cancer can predict whether patients will develop a brain metastasis later and are high risk. The inability to predict which patients will develop brain metastases limits our ability to best treat these patients to provide them with the best outcomes, since current practice is typically to treat brain metastases after they develop rather than to prevent them. Accordingly, this work aims to identify DNA methylation signatures in lung, breast, and melanoma cancers that are detectable in patient blood samples and that predict whether they will later metastasize to the brain in patients. By arming physicians with tools that provide this risk information for their patients after non-invasive blood sampling, the extent of treatment offered to patients can be matched to their level of risk and this may allow for strategies to prevent brain metastases in high risk patients. Overall, non-invasively determining a patient's risk for spread of their cancer to their brain allows for tailored treatment aiming to improve patient survival and quality of life.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Zuccato, Jeffrey A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~